We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 114,164 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/2/2018 11:55 | Vindictive? I stated an opinion based on my experience. Are part of the new generation of young people that require a 'safe space' away from confronting opinions that do not conform with yours? | incanus | |
15/2/2018 15:19 | It is normal for a company share price to rise in anticipation of a divi just as it is normal for the share price to depreciate by about the same amount ex divi. SBTX may decline more significantly if there is no locked shares. Naivety is astonishing. Let us hope management in both companies have some substance to shore up both shares. | incanus | |
15/2/2018 12:57 | The barrier cream in development at SBTX that kills pathogens without alcohol is going to be the best solution for hospitals and medical workers especially as the definition of hygiene changed last year in favour of microbial type creams. SBTX is developing a world beater barrier cream imo. | bobalot | |
13/2/2018 15:15 | just bought some more at 8.28 -rude not to | malreid | |
13/2/2018 11:37 | Maybe a II is starting to accumulate. | bobalot | |
13/2/2018 10:17 | this looks bust | lucicavi | |
13/2/2018 10:10 | 500k share buy just gone through! | rafboy | |
09/2/2018 13:05 | PRESENTATION FREE TICKETS: SkinBioTherapeutics Retweeted SHARES magazine Free tickets now available to our investor event in Manchester on 20 Feb Companies presenting include Angle, First Sentinel and SkinBio Therapeutics Prize draw on the night - chance to win Sale Sharks tickets + more … | bobalot | |
07/2/2018 15:56 | JJ - I would hope the divi will follow progressive news in favour of commercial progress here and perhaps some form of lock-in period so SBTX shares don't just flood the market. SOH has always suggested the divi will be handled in such a way that neither OPTI or SBTX holders suffer negatively. That would be some conjuring trick. | elrico | |
07/2/2018 14:56 | The current share price is an excellent entry price that is likely to multi-bag from here in a few months imo. | bobalot | |
07/2/2018 14:41 | Just what is it now, well below IPO! | rafboy | |
07/2/2018 11:31 | The OPTI share price will fall on reduced asset valuation and there will be no change at SBTX because of the lock in. Eventually the liquidity in SBTX will increase which is very positive. | bobalot | |
07/2/2018 08:11 | I wonder what will happen to the share price when Opti holders are given their shares? | judijudi | |
06/2/2018 13:45 | The microbiome is becoming massive news and that is why Dr. Cath will be promoting her research and SBTX at four presentations very soon. Take a look at these conferences: Event date: March 8th Event dates: Manchester – 20 February 2018 there is another presentation on Feb 21st probably in Manchester. Edinburgh – 28 February 2018 | bobalot | |
06/2/2018 10:41 | Buying at 8.2p! Had to grab a few more. | jestercat2 | |
06/2/2018 10:26 | ps .. didn't mean to sound patronizing there | onedayrodders | |
06/2/2018 09:08 | Dr.Cath will be promoting the business at four events between later this month and early March prior to the human trials of the cosmetic cream. Perhaps more news releases coming our way soon imo. SBTX is a gift at these discounted prices. | bobalot | |
06/2/2018 08:55 | Crazy over-reaction. Just bought 31K at 8.2p! My lowest purchase price of SBTX. | parob | |
01/2/2018 15:42 | These events and publications are worth tracking: Dr. Cath is a speaker at the European event being held in Holland: Microbiome R&D and Business Collaboration Forum: Europe 21st-22nd Mar 2018. Microbiome Futures is a landmark event that will document the future of microbiome research and commercialisation. A half day panel discussion – reporting on KOL research and audience consultation 250 participants from leading companies and institutions Outcomes to be published in Nature Biotechnology Gala networking dinner The live event, on May 23, will be the culmination of a thorough research process during which the working group will be gathering input from a global pool of stakeholders in the microbiome space. They will come prepared, having researched and discussed issues from the science of moving from correlation to causation to practical solutions to data and regulatory hurdles. | bobalot | |
01/2/2018 06:44 | Cath is well known to several global players as she has researched and tested for boots and j and j I believe. I'm terry sure they are being kept in the loop on progress. Cap way too low for me. Just needs volume so happy to buy when it's quiet when funds allow. | shrewdmole | |
01/2/2018 06:42 | The organisers of the conference said:"Following the mainstream focus on the gut microbiome and its role in health and disease, researchers and industry experts are now turning their attention towards the emerging relationship between the skin microbiome and healthy skin. This has the potential to revolutionise the beauty and personal care industry," | parob | |
31/1/2018 22:13 | Interest building in the sector. Think this is the first conference I’ve seen specifically for the skin microbiome sector: Skin Microbiome Conference set for May 2018 31-Jan-2018 | parob |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions